SequelSEC

Century Therapeutics, Inc. IPSC

Biological Products, (No Diagnostic Substances) · CIK 0001850119 · Fiscal year ends 1231

Revenue
$6.59M
Fiscal year ended 2024-12-31
Operating income
-$138.14M
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

Valuation, from the filing

Public float$212.51MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.18Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.9×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.3×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth1556.8%99th
SBC / revenue6.3%15th
CapEx / revenue0.8%20th
Net margin-8.8%78th
Operating margin-15.8%78th
FCF margin-95.9%64th
Current ratio5.97x61th

Century Therapeutics, Inc. (IPSC) reported revenue of $6.59M and net income of -$126.57M for the fiscal year ended 2024-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Century Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Century Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Revenue$6.59M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$138.14M
Net income-$126.57M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$124.78M
Income tax expense$1.79M
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$33.16M
Selling & marketingUnavailable

Balance

Century Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Cash & equivalents$58.44M
Total assets$353.22M
Current assets$194.05M
Total liabilities$191.85M
Current liabilities$129.78M
Total equity incl. NCI$161.36M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$3.08M

Cash flow

Century Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Operating cash flow-$110.14M
Capital expendituresUnavailable
Investing cash flow$47.48M
Financing cash flow$74.56M
Net change in cashUnavailable
Stock-based compensation$12.69M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Century Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-31
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-2096.2%
FCF marginUnavailable
SBC / revenue192.5%
Current ratio1.50x
Revenue YoY growth194.9%
Net margin-1920.6%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IPSC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.